Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate


Wednesday, March 4, 2015

Hepatitis C study for District residents

Unity Health Care announced a study to show how health care providers can treat Hepatitis C. 

WASHINGTON (WUSA9) -- Hepatitis C is a contagious liver disease, complications can lead to death. Affecting over 3 million people in the US, the disease is particularly dangerous because there are few noticeable symptoms early on.

Wednesday evening, Unity Health Care announced a study to show how health care providers can treat Hepatitis C.

Called the ASCEND study, 600 DC patients will be treated with Harvoni, a newly FDA approved medication. Unity Health Care is partnering with the National Institutes of Health, the University of Maryland, and Family and Medical Counseling Services Inc. to conduct the research.

Source:  http://www.wusa9.com/story/news/2015/03/04/hepatitis-c-unity-heath/24395001/
Posted by at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)